REFERENCES
- Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007),[1] cert denied, 552 U.S. 1159 (2008).
- Balasubramanian, G., S. Morampudi, P. Chhabra, A. Gowda, and B. Zomorodi. 2016. An overview of compassionate use programs in the European Union member states. Intractable & Rare Diseases Research 5(4): 244–254. doi: 10.5582/irdr.2016.01054.
- Bartlett, V. L., S. S. Dhruva, N. D. Shah, P. Ryan, and J. S. Ross. 2019. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Network Open 2 (10):e1912869. doi: 10.1001/jamanetworkopen.2019.12869.
- Baumfeld Andre, E., R. Reynolds, P. Caubel, L. Azoulay, and N. A. Dreyer. 2019. Trial designs using real‐world data: The changing landscape of the regulatory approval process. Pharmacoepidemiology and Drug Safety. doi: 10.1002/pds.4932.
- Chapman, C. R., K. I. Moch, A. McFadyen, L. Kearns, T. Watson, P. Furlong, and A. Bateman-House. 2019. What compassionate use means for gene therapies. Nature Biotechnology 37(4): 352–355. doi: 10.1038/s41587-019-0081-7.
- European Parliament Regulation (EC) No 726/2004 Article 83 no. 2.
- FDA. 2019. FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with cancer. https://www.fda.gov/news-events/press-announcements/fda-announces-project-facilitate-assist-physicians-seeking-access-unapproved-therapies-patients
- Fisher, C. K., A. M. Smith, and J. R. Walsh. 2019. Machine learning for comprehensive forecasting of Alzheimer’s Disease progression. Scientific Reports 9(1): 1–14. doi: 10.1038/s41598-019-49656-2.
- Gliklich, R. E., and M. B. Leavy. 2019. Assessing real-world data quality: The application of patient registry quality criteria to real-world data and real-world evidence. Therapeutic Innovation & Regulatory Science 54(2): 303–307. doi: 10.1177/2168479019837520.
- Grieves, M. 2019. Virtually intelligent product systems: Digital and physical twins. In Complex systems engineering: Theory and practice, ed. S. Flumerfelt et al., 175–200. Reston, VA: American Institute of Aeronautics and Astronautics.
- Jarow, J. P., and R. Moscicki. 2017. Impact of expanded access on FDA regulatory action and product labeling. Therapeutic Innovation & Regulatory Science 51(6): 787–789. doi: 10.1177/2168479017707800.
- Klonoff, D. C. 2020. The expanding role of real-world evidence trials in health care decision making. Journal of Diabetes Science and Technology 14(1): 174–179. doi: 10.1177/1932296819832653.
- London, A. J., and J. Kimmelman. 2020. Against pandemic research exceptionalism. Science (New York, N.Y.) 368(6490): 476–477. doi: 10.1126/science.abc1731.
- McKee, A. E., A. O. Markon, K. M. Chan‐Tack, and P. Lurie. 2017. How often are drugs made available under the Food and Drug Administration’s expanded access process approved? The Journal of Clinical Pharmacology 57: S136–S142. doi: 10.1002/jcph.960.
- Miller, J. E., J. S. Ross, K. I. Moch, and A. L. Caplan. 2017. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Research Notes 10(1): 350. doi: 10.1186/s13104-017-2687-5.
- PWC 2016. The Early Access to Medicines Scheme (EAMS): An independent review. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/509612/eams-review.pdf
- Reagan-Udall Foundation. 2018. Leveraging real-world treatment experience from expanded access protocols. https://reaganudall.org/news-and-events/announcements/report-leveraging-real-world-treatment-experience-expanded-access
- Sherman, M., Z. Idan, and D. Greenbaum. 2019. Who watches the step-watchers: The ups and downs of turning anecdotal citizen science into actionable clinical data. American Journal of Bioethics 19(8): 44–46. doi: 10.1080/15265161.2019.1619873.
- Young, F. E., J. A. Norris, J. A. Levitt, and S. L. Nightingale. 1988. The FDA’s new procedures for the use of investigational drugs in treatment. JAMA 259(15): 2267–2270. doi: 10.1001/jama.1988.03720150043034.
- Zoffer, W. 2019. Recent legislation that secured a ‘Right to try’ unapproved drugs: Why the ‘fuss’ over a ‘fix’of what ‘ain’t broke’? Wake Forest Journal of Law & Policy. https://ssrn.com/abstract=3511840